Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients clinical trial (NCT03571360). Contact the study team or your healthcare provider for specific answers.

Question 2

How does pembrolizumab compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients clinical trial (NCT03571360). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients clinical trial (NCT03571360). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients clinical trial (NCT03571360). Contact the study team or your healthcare provider for specific answers.

Question 5

What kind of tests will be done to monitor my response to the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients clinical trial (NCT03571360). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my cancer progresses during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients clinical trial (NCT03571360). Contact the study team or your healthcare provider for specific answers.

What this study is about